



PRESS RELEASE
For immediate release

PERCEPTRONIX EARNS U.S. PATENT FOR LUNG CANCER DETECTION TECHNOLOGY

VANCOUVER, CANADA (February 18, 2005) – Perceptronix Medical Inc., (“Perceptronix”) today announced that the United States Patent and Trademark Office has granted to Perceptronix patent number 6,826,424 entitled “Methods and apparatus for fluorescence and reflectance imaging and spectroscopy and for contemporaneous measurement of electromagnetic radiation with multiple measuring devices”.

Fluorescence bronchoscopy has enabled a 2 to 6 fold increase in the ability of physicians to detect early stage cancer in the central airways of the lung. This is an important improvement for lung cancer patients as early diagnosis can dramatically improve survival rates. Lung cancer remains the leading cause of cancer death for both men and women in Canada and much of the developed world. Of the more than 21,000 Canadians that are diagnosed with lung cancer every year, fewer than 15% will survive 5 years. Perceptronix believes that the technology described in this new patent could reduce the time required to conduct the fluorescence bronchoscopy examination and that the spectral measurements could significantly improve the specificity of the procedure.

“By combining familiar white light navigation with the increased sensitivity of fluorescence for early lung cancer localization, this technology could cut the time required for a typical fluorescence exam to almost half the time it currently takes – making this procedure rival a white light only procedure. The spectral measurements could reduce the number of biopsies taken that prove to be of benign conditions. Improved speed and fewer biopsies would reduce patient discomfort and risk and improve the utility of fluorescence bronchoscopy which may improve patient access to this potentially life-saving diagnostic technology”, said Dr. David Garner, Perceptronix President and Chief Operating Officer.

About Perceptronix Medical Inc.

Perceptronix (www.perceptronix.com) is a private cancer diagnostics medical device company based in Vancouver, Canada. The Company’s goal is to commercialize technologies to improve the early detection, localization, and diagnosis of cancer, with an initial focus on products to improve the early diagnosis of lung cancer. Perceptronix was founded in June, 1999 as a spin-off company of the BC Cancer Agency (www.bccancer.bc.ca), a world-leader in cancer care and research, with a particularly notable track record in pioneering early cancer detection programs.

Contact:

Lydia Taylor
Director of Business Development,
Perceptronix Medical Inc.
Ste. 400, 555 West 8th Avenue
Vancouver, BC V5Z 1C6
Phone: (604) 707 – 9037
info@perceptronix.com